{"entity":{"id":"idea-cost-subcutaneous-community","kind":"idea","name":"Give subcutaneous immunotherapy in community clinics and at home","aka":[],"tldr":"Under-the-skin versions of atezolizumab, nivolumab and pembrolizumab take minutes rather than an hour and need no infusion chair, so they can be given by a nurse near home, cutting facility fees and travel.","summary":"The FDA approved subcutaneous atezolizumab (2024), nivolumab (2024) and pembrolizumab (2025), each with hyaluronidase to allow a large-volume injection over a few minutes. The clinical benefit is equivalent; the economic benefit depends on where the injection is given. Delivered in a community clinic or by a home-visiting nurse, the injection avoids hospital facility fees, infusion-suite capacity and long journeys. Payment rules that require an infusion setting, and the drug's Part B status, currently blunt the saving.","asOf":"2026-09-10","links":[{"label":"FDA: Drugs@FDA approved labels","url":"https://www.accessdata.fda.gov/scripts/cder/daf/"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["atezolizumab","nivolumab","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-care-fragmentation","b-drug-pricing","b-workforce","b-global-access"],"keyPapers":["paper-checkmate-017-nejm-2015","paper-keynote-189-nejm-2018","paper-niche-2-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Community or home administration of subcutaneous checkpoint inhibitors will cut per-dose administration and patient travel costs by more than half against hospital infusion, with equal safety and adherence.","rationale":"Subcutaneous trastuzumab and rituximab have been given in community settings in Europe for a decade; the barrier is payment policy, not clinical.","test":"A randomised or stepped comparison of hospital versus community administration on cost, time, patient-reported burden and adverse events.","maturity":"early-clinical","actor":"clinic","cost":"medium","horizonYears":3},"route":"/ideas/idea-cost-subcutaneous-community/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"bottleneck":[{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"paper":[{"id":"paper-checkmate-017-nejm-2015","kind":"paper","name":"CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy","route":"/key-papers/paper-checkmate-017-nejm-2015/"},{"id":"paper-keynote-189-nejm-2018","kind":"paper","name":"KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation","route":"/key-papers/paper-keynote-189-nejm-2018/"},{"id":"paper-niche-2-nejm-2024","kind":"paper","name":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","route":"/key-papers/paper-niche-2-nejm-2024/"}]}}